News about "obesity treatment "

Wegovy Pill Prescriptions Surpass 3 Million as Novo Nordisk Presents New ADA 2026 Data

Novo Nordisk announced that Wegovy pill prescriptions have surpassed 3 million since launch, marking one of the largest US pharmaceutical launches by volume. Most prescriptions are from people new to GLP-1 therapy, expanding access to obesity treatment, while new clinical analyses are being presented at ADA 2026.

Obesity Treatment | 10/06/2026 | By News Bureau

Pfizer's Berobenatide Shows Strong Phase 2b Results with Monthly Dosing

Pfizer’s GLP-1 receptor agonist berobenatide demonstrated robust efficacy and favorable tolerability in a Phase 2b trial, supporting once-monthly dosing.

Obesity Treatment | 08/06/2026 | By News Bureau

Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE, First Market Outside the US

UAE becomes first country outside the United States to offer the oral semaglutide treatment for obesity, marking a key step in Novo Nordisk’s global expansion plans.

Obesity Treatment | 04/06/2026 | By News Bureau

Harbour BioMed Reports Promising Preclinical Data for AI-Driven Drug Candidate LET003

Harbour BioMed announced promising preclinical data for LET003, its first Artificial Intelligence (AI)-enabled drug candidate, highlighting potential as a next-generation obesity therapy targeting ACVR2A/2B.

Obesity Treatment | 18/05/2026 | By News Bureau |  268

Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials

Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.

Obesity Treatment | 13/05/2026 | By News Bureau |  105

Neuland Laboratories Partners with LIR Life Sciences Corp to Advance Transdermal GLP-1 Obesity Therapy

Neuland Laboratories partnership with LIR Life Sciences Corp will focus on developing and manufacturing cell-penetrating peptides to support LIR Life’s patch-based GLP-1/GIP obesity treatment platform.

Obesity Treatment | 07/05/2026 | By News Bureau |  123

Neurocrine Initiates First-in-Human Trial for Novel Obesity Therapy NBIP-2118

Neurocrine launches phase I trial of NBIP-2118, a novel CRF2 agonist aimed at delivering fat-specific weight loss while preserving muscle in obesity treatment.

Obesity Treatment | 05/05/2026 | By News Bureau |  126

UK MHRA Approves Single-Dose 7.2mg Wegovy Injection for Obesity Treatment

The UK Medicines and Healthcare products Regulatory Agency has approved a single-dose 7.2mg Wegovy pen, simplifying weekly treatment for adults with obesity and a BMI of 30 or higher.

Obesity Treatment | 15/04/2026 | By News Bureau |  140

Hoth Therapeutics Reports Positive HT-VA CRADA Data

Hoth Therapeutics reports positive HT-VA data showing GDNF improves liver fat metabolism, reduces fat production and may outperform semaglutide in MAFLD and obesity.

Obesity Treatment | 14/04/2026 | By News Bureau |  160

MetaVia Advances Obesity Drug Development with First Patient Dosed in DA-1726 Phase I Trial

MetaVia initiates Part 3 of its phase I trial for DA-1726, evaluating higher-dose strategies to enhance weight loss, metabolic outcomes and tolerability in obesity and cardiometabolic disease treatment.

Obesity Treatment | 13/04/2026 | By News Bureau